William Blair initiated coverage of Thermo Fisher with a rating of Outperform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/11/2025 | $660.00 | Neutral → Buy | Citigroup |
| 12/9/2025 | $685.00 | Buy | Goldman |
| 12/8/2025 | $750.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 12/2/2025 | $670.00 | Overweight | Morgan Stanley |
| 12/1/2025 | $670.00 | Hold → Buy | HSBC Securities |
| 9/11/2025 | $550.00 | Equal Weight → Overweight | Barclays |
| 8/19/2025 | Outperform | William Blair | |
| 7/24/2025 | $510.00 | Buy → Hold | HSBC Securities |
Citigroup upgraded Thermo Fisher from Neutral to Buy and set a new price target of $660.00
Goldman initiated coverage of Thermo Fisher with a rating of Buy and set a new price target of $685.00
KeyBanc Capital Markets upgraded Thermo Fisher from Sector Weight to Overweight and set a new price target of $750.00
OlivePoint Capital ("OlivePoint"), an institutional real estate investment manager focused on thematic and special situations strategies, and Redwood Capital Management, LLC, a global alternative investment manager focused on opportunistic credit and other special situation investments ("Redwood Capital"), today announced its acquisition of 3900 Paramount Parkway, a 220,000-square-foot Class A office building located within Research Triangle Park (RTP) in Raleigh–Durham, one of the fastest-growing innovation hubs in the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215054691/en/3900 Paramount Parkway - Raleigh,
New and expanded facilities provide local expertise, advanced technologies and tailored support for biopharma innovators throughout the region Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region's rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network designed to enhance speed, efficiency and sustainability in biomanufacturing. Asia is an emer
Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher") announced today that it has priced an offering of €2.1 billion aggregate principal amount (the "Offering") of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the "floating rate notes") at the issue price of 100.000% of their principal amount; and €1,100,000,000 aggregate principal amount of its 3.628% senior notes due 2035 (the "fixed rate notes," and together with the floating rate notes, the "notes") at the issue price of 100.000% of their
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
CERT - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
144 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)
8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as
Jim Meyer to Become Chief Financial Officer, Effective March 1, 2026 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that Stephen Williamson, senior vice president and chief financial officer (CFO), has decided to retire from the company, effective March 31, 2026. The company's board of directors has approved the appointment of Jim Meyer, currently vice president of financial operations, to succeed Williamson as CFO, effective March 1, 2026. Williamson, age 58, has led Thermo Fisher's global finance organization as CFO since 2015. He joined the company in 2001 as Vice President, European Financial Operations. To ensure a seamless transition
908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead
OlivePoint Capital ("OlivePoint"), an institutional real estate investment manager focused on thematic and special situations strategies, and Redwood Capital Management, LLC, a global alternative investment manager focused on opportunistic credit and other special situation investments ("Redwood Capital"), today announced its acquisition of 3900 Paramount Parkway, a 220,000-square-foot Class A office building located within Research Triangle Park (RTP) in Raleigh–Durham, one of the fastest-growing innovation hubs in the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215054691/en/3900 Paramount Parkway - Raleigh,
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.43 per common share, payable on January 15, 2026, to shareholders of record as of December 15, 2025. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the dev
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 27, 2025. Third Quarter Highlights Third quarter revenue grew 5% to $11.12 billion. Third quarter GAAP diluted earnings per share (EPS) was $4.27, in-line with the prior-year quarter. Third quarter adjusted EPS grew 10% to $5.79. Delivered excellent operational performance in the quarter demonstrating the strength of our proven growth strategy, the power of our PPI Business System, and the continued active management of our company. Advanced our proven growth strategy, launching a range of high-impact, innovative new p
SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)
SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)